We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





Ultra-Specific, Non-Invasive Saliva Test Enables Quantitative Testing Of COVID-19 Antibodies

By LabMedica International staff writers
Posted on 09 Dec 2020
Print article
Illustration
Illustration
A home-collection assay for the quantitative testing of COVID-19 antibodies using saliva now makes it possible for individuals to monitor the level of their COVID-19 antibodies over time without leaving home.

Liquid Diagnostics (San Clemente, CA, USA) has developed and successfully carried out CLIA validation of the test which utilizes the company’s proprietary Amperial technology and measures IgG to the S1 domain of the SARS-CoV-2 spike protein. The Amperial chemistry is based on immobilizing biomolecules in a conducting gel matrix and measuring current following electrochemical detection.

This quantitative COVID-19 antibody test is the first home-collection, ultra-specific, non-invasive saliva test. The test is perfect for monitoring both epidemiologic and vaccine response studies because of its unparalleled specificity of this assay and because individuals can collect samples with an easy-to-use mouth swab at home and mail the sample to a centralized laboratory. Results can be returned the day following the receipt of the sample. Individuals can be tested multiple times to assess the persistence of COVID-19 antibody production following exposure or vaccination.

A CLIA evaluation showed that the test has a specificity (absence of false negatives) of at least 99.994% and a positive predictive value of > 96% (the percentage of positive tests that are true positives). The test is classified as a Laboratory Developed Test. An emergency use authorization (EUA) application has been filed and is awaiting FDA clearance.

"With increasing evidence that the presence of SARS-CoV-2 antibodies correlates with immunity to infection, our Amperial assay with its exquisite specificity and high positive predictive value could be useful for essential workers to determine if they have already had a COVID-19 infection and developed immunity," said Dr. Charles Strom, CEO of Liquid Diagnostics, LLC. "Because it quantifies the amount of antibodies, the test could be used to track the persistence of antibodies following infection or vaccination to assess the potential need for booster shots."

Related Links:
Liquid Diagnostics

Gold Supplier
Flock Tipped Applicator
HydraFlock 6" Sterile Large Flock Swab w/Polystyrene Handle, 80mm Breakpoint
New
Gliadin IgG Test
Gliadin IgG Test System
New
Rapid HBsAg Immunoassay
Imuno-RÁPIDO HBsAg
New
Rapid Saliva-Based Pregnancy Test
Salistick

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more

Pathology

view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.